A roundtable discussion, moderated by Thomas Martin, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, focused on CAR Tcell therapy considerations in the treatment of multiple myeloma, including data on approved CART options and a look at the pipeline. Dr. Martin was joined by a panel that included Sagar Lonial, MD, FACP; Peter Voorhees, MD; and Shambavi Richard, MD.

In the next segment of the roundtable series, the panel debates whether CART can be moved earlier in the course of myeloma treatment, including a discussion on the KarMMa2 and KarMMa3 trials assessing idecabtagene vicleucel in different clinical scenarios and the CARTITUDE2 cohorts receiving ciltacabtagene autoleucel.